ArticleOpen forum infectious diseases2018
Human Immunodeficiency Virus/Hepatits C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significant.
Article in Open forum infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 28 citations in OpenAlex.
- Trends in Hepatitis C Virus Infection Prevalence Among People With HIV in Spain Over 2 Decades (2002-2023).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Impact of HCV elimination on metabolism markers in people living with HIV.Scientific reports · 2025Article
- Control and Elimination of Hepatitis C Virus Among People With HIV in Australia: Extended Follow-up of the CEASE Cohort (2014-2023).Open forum infectious diseases · 2024Article
- Cohort Profile: International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC).International journal of epidemiology · 2024Article
- Epidemiological trends of HIV/HCV coinfection in Spain, 2015-2019.HIV medicine · 2022Article
- Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review.Scientific reports · 2021Article
- Quantifying transmission dynamics of acute hepatitis C virus infections in a heterogeneous population using sequence data.PLoS pathogens · 2021Article
- HIV/HBV coinfection: temporal trends and patient characteristics, Spain, 2002 to 2018.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2021Article
- What is needed to achieve HCV microelimination among HIV-infected populations in Andalusia, Spain: a modeling analysis.BMC infectious diseases · 2020Article
- Human immunodeficiency virus and hepatotropic viruses co-morbidities as the inducers of liver injury progression.World journal of gastroenterology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
48 authors at 20 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe assessed the prevalence of antibodies against hepatitis C virus (HCV-Abs) and active HCV infection in patients infected with human immunodeficiency virus (HIV) in Spain in 2016 and compared the results with those of similar studies performed in 2002, 2009, and 2015.
methodsThe study was performed in 43 centers during October-November 2016. The sample was estimated for an accuracy of 2% and selected by proportional allocation and simple random sampling. During 2016, criteria for therapy based on direct-acting antiviral agents (DAA) were at least significant liver fibrosis, severe extrahepatic manifestations of HCV, and high risk of HCV transmissibility.
resultsThe reference population and the sample size were 38904 and 1588 patients, respectively. The prevalence of HCV-Abs in 2002, 2009, 2015, and 2016 was 60.8%, 50.2%, 37.7%, and 34.6%, respectively (
conclusionsOur findings suggest that with universal access to DAA-based therapy and continued efforts in prevention and screening, it will be possible to eliminate active HCV among HIV-infected individuals in Spain in the short term. However, the burden of HCV-related cirrhosis will continue to be significant among HIV-infected individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.